title: Methylation impact analysis of erythropoietin (EPO) Gene to hypoxia inducible factor-1α (HIF-1α) activity.
abstract: Erythropoietin (EPO) is a glycoprotein hormone that play a role as key regulator in the production of red blood cells. The promoter region of EPO is methylated in normoxic (non-hypoxia) condition, but not in hypoxic condition. Methylation of the EPO enhancer region decline the transcription activity of EPO gene. The aim of this study is to investigate how different methylation percentage affected on the regulation and transcriptional activity of EPO gene. The DNA sequence of erythropoietin gene and protein sequence was retrieved from the sequence database of NCBI. DNA structure was constructed using 3D-DART web server and modeling structure of HIF1 predicted using SWISS-MODEL web server. Methylated DNA sequence of EPO gene using performed with YASARA View software and docking of EPO gene and transcription factor HIF1 analyzed by using HADDOCK webserver. Our result showed that binding energy in 46% methylated DNA was higher (-161,45 kcal/mol) than in unmethylated DNA (-194,16 kcal/mol) and 8% methylated DNA (-175,94 kcal/mol). So, we presume that a silencing mechanism of the Epo gene by methylation is correlated with the binding energy, which is required for interaction. A higher methylation percentage correlates with a higher binding energy which can cause an unstable interaction between DNA and transcription factor. In conclution, methylation of promoter and enhancer region of Epo gene leads to silencing.
authors.affiliation: Department of Biology, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, East Java, Indonesia.
authors.forename: Firli Rahmah Primula
authors.initials: FR
authors.lastname: Dewi
authors.forename: Fatchiyah
authors.initials: F
authors.lastname: Fatchiyah
keywords: EPO; HIF-1; methylation; promoter; transcription
references.citation: Mol Cell Biol. 2002 Oct;22(19):6689-96
references.pmid: 12215526
references.citation: J Comput Chem. 2004 Oct;25(13):1605-12
references.pmid: 15264254
references.citation: Nucleic Acids Res. 1997 Dec 15;25(24):4940-5
references.pmid: 9396800
references.citation: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W235-9
references.pmid: 19417072
references.citation: Nucleic Acids Res. 2009 Jan;37(Database issue):D387-92
references.pmid: 18931379
references.citation: Blood. 2000 Jan 1;95(1):111-9
references.pmid: 10607693
references.citation: Cancer Lett. 2000 Sep 1;157(2):169-76
references.pmid: 10936677
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):332-9
references.pmid: 16428469
references.citation: Genes Cancer. 2011 Jan;2(1):65-73
references.pmid: 21779481
references.citation: Nat Protoc. 2010 May;5(5):883-97
references.pmid: 20431534
references.citation: Nature. 2007 May 24;447(7143):425-32
references.pmid: 17522676
references.citation: Proteins. 2003 Feb 15;50(3):437-50
references.pmid: 12557186
references.citation: Methods Enzymol. 2007;435:179-97
references.pmid: 17998055
references.citation: Nucleic Acids Res. 2010 Jul;38(Web Server issue):W445-9
references.pmid: 20444869
references.citation: Cell. 2007 Feb 23;128(4):669-81
references.pmid: 17320505
references.citation: World J Gastroenterol. 2006 Jan 14;12(2):234-9
references.pmid: 16482623
references.citation: Blood. 1999 Sep 15;94(6):1864-77
references.pmid: 10477715
references.citation: J Biol Chem. 1999 Apr 23;274(17):12115-23
references.pmid: 10207038